A Phase 2 Study to Assess Dose-response Relationship of HCP1803 in Patients With Essential Hypertension
Status:
Unknown status
Trial end date:
2019-11-30
Target enrollment:
Participant gender:
Summary
A multicenter, randomized, double-blind, parallel, phase 2 study to assess dose-response
relationship of HCP1803 in patients with essential hypertension